Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S260100
Reexamination Certificate
active
07977342
ABSTRACT:
The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.
REFERENCES:
patent: 6476031 (2002-11-01), Chakravarty et al.
patent: 2004/0038856 (2004-02-01), Chakravarty et al.
patent: 2008/0182863 (2008-07-01), Simmen et al.
patent: 2009/0131460 (2009-05-01), Simmen et al.
patent: 2009/0156595 (2009-06-01), Raboisson et al.
patent: 2295387 (1996-05-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 01/47921 (2001-07-01), None
patent: WO 02/22601 (2002-03-01), None
patent: WO 02/076976 (2002-10-01), None
patent: WO 03/077921 (2003-09-01), None
patent: WO 03/078423 (2003-09-01), None
patent: WO 03/078426 (2003-09-01), None
patent: WO 03/078427 (2003-09-01), None
patent: WO 03/097615 (2003-11-01), None
patent: WO 2004/047818 (2004-06-01), None
patent: WO 2004/048930 (2004-06-01), None
patent: WO 2004/065392 (2004-08-01), None
patent: WO 2004/074270 (2004-09-01), None
patent: WO 2004/087056 (2004-10-01), None
patent: WO 2005/032481 (2005-04-01), None
patent: WO 2006/100310 (2006-09-01), None
patent: WO 2006/105063 (2006-10-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Kimura, et. al., Journal of Infectious Diseases, (2006); 193, 1371-4.
Choo, Qui-Lim et al., “Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome”, Science, Apr. 21, 1989, pp. 359-362, vol. 244.
Cooper, Kelvin et al., “Bicyclo[3.3.0]octenones in Synthesis. An Approach to the Synthesis of the Antitumor Sesquiterpene Quadrone”, J. Chem. Soc. Perkin Trans., 1984, pp. 799-809, vol. 1.
Dowd, Paul et al., “Free Radical Ring-Expansion Leading to Novel Six- and Seven-Membered Heterocycles”, Tetrahedron, 1991, pp. 4847-4860, vol. 47, No. 27.
Goodman & Gilman's the Pharmacological Basis of Therapeutics.
Greco, Michael N. et al., “Highly Stereoselective Synthesis of Substituted Hydrindanes Related to the Antiepileptic Drug Topiramate”, Tetrahedron Letters, 1992, pp. 5009-5012, vol. 33, No. 35.
Kim, W. Ray, “The Burden of Hepatitis C in the United States”, Hepatology, 2002, pp. 530-534, vol. 36, No. 5, Suppl. 1.
Kolykhalov, Alexander A. et al., “Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3' Nontranslated Region Are Essential for Virus Replication In Vivo”, Journal of Virology, Feb. 2000, pp. 2046-2051, vol. 74, No. 4.
Krieger, Nicole et al., “Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations”, Journal of Virology, May 2001, pp. 4614-4624, vol. 75, No. 10.
Lauer, Georg M. et al., “Hepatitis C Virus Infection”, New Engl. J. Med., Jul. 5, 2001, pp. 41-52, vol. 345, No. 1.
Lohmann, V. et al., “Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line”, Science, Jul. 2, 1999, pp. 110-113, vol. 285.
Moyer, Mikel P. et al., Intramolecular N-H, O-H and S-H Insertion Reactions. Synthesis of Heterocycles from α-Diazo β-Keto Esters, J. Org. Chem., 198, pp. 5223-5230, vol. 50, year issued: 1985.
National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-Jun. 10-12, 2002, Hepatology, Nov. 2002, pp. S3-S-20.
Wolff, Manfred E. et al., Thia Steroids. III. Derivatives of 2-Thia-A-nor-5α-androstan-17β-ol As Probes of Steroid-Receptor Interactions, Journal of Medicinal Chemistry, 1970, pp. 531-534, vol. 13, No. 3.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 11/914,044 dated Apr. 29, 2010, 7 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/914,044 dated Sep. 3, 2009, 11 pages.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 11/909,118 dated Jul. 13, 2009, 11 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/909,118 dated Dec. 30, 2008, 15 pages.
Murata et al., “Suppression of Hepatitis C Virus Replicon by TGF-β,”Virology, 331: 407-417, 2005.
Valentino J. Stella, “Prodrugs as Therapeutics,”Expert Opinion on Therapeutic Patents, 14(3): 277-280, 2004.
Manfred E. Wolff, “Some Considerations for Prodrug Design,”Burger's Medicinal Chemistry and Drug Discovery, 5thEd., vol. 1, 975-977, 1994.
Bernard Testa, “Prodrug Research: Futile or Fertile?”Biochemical Pharmacology68: 2097-2106, 2004.
Ettmayer et al., “Lessons Learned from Marketed and Investigational Prodrugs,”Journal of Medicinal Chemistry, 47(10): 2393-2404, 2004.
Lenz Oliver
Lin Tse-I
Raboisson Pierre Jean-Marie Bernard
Simmen Kenneth Alan
Surleraux Dominique Louis Nestor Ghislain
Murray Jeffrey H
Tibotec-Virco Virology BVBA
Wilson James O
LandOfFree
HCV inhibiting bi-cyclic pyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HCV inhibiting bi-cyclic pyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV inhibiting bi-cyclic pyrimidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734578